Tag: Nplate

In a long-term, single-arm study, Nplate (romiplostim) was found to be generally safe and well-tolerated for up to 5 years, with the incidence of adverse events not increasing with longer exposure. However, like many medications, understanding what are the long-term effects of Nplate is crucial for patient safety and management.

In a 2011 Phase 3 trial, 91% of patients treated with Nplate achieved a doubling of their baseline platelet count to at least 50,000 per microliter, while 93% achieved an increase of at least 20,000 per microliter from baseline. This impressive data highlights the effectiveness of romiplostim (Nplate) for increasing platelet levels in patients with immune thrombocytopenia (ITP) who have not responded adequately to other therapies.

In a key clinical study, the median time to initial platelet response for Nplate was 2.1 weeks, but individual responses can vary significantly. This initial response is just the beginning of a process to achieve and maintain stable platelet levels over time.